The most-cited Articles on
Central Nervous System Tumors

Hachem LD et al., Citation classics in neuro-oncology: assessment of historical trends and scientific progress. Neuro Oncol 2017


Home > Publications > The most-cited articles > Central nervous system tumors > Hachem LD, 2017


Contents

◽◽◽

Hachem LD, Mansouri A, Juraschka K, Taslimi S, Pirouzmand F, Zadeh G.
Citation classics in neuro-oncology: assessment of historical trends and scientific progress.
Neuro Oncol. 2017 Sep 1;19(9):1158-1172. doi: 10.1093/neuonc/nox053. PMID: 28531344. Bibliometric analysis.




Classification


Etiology, Pathogenesis, Pathology


Overall management


Treatment



Classification

Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P.
Grading of astrocytomas. A simple and reproducible method.
Cancer. 1988 Nov 15;62(10):2152-65. doi: 10.1002/1097-0142(19881115)62:10<2152::aid-cncr2820621015>3.0.co;2-t. PMID: 3179928. Tool development.



Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK.
The WHO classification of tumors of the nervous system.
J Neuropathol Exp Neurol. 2002 Mar 1;61(3):215-25. doi: 10.1093/jnen/61.3.215. PMID: 11895036. Review.



Kleihues P, Burger PC, Scheithauer BW.
The new WHO classification of brain tumours.
Brain Pathol. 1993 Jul;3(3):255-68. doi: 10.1111/j.1750-3639.1993.tb00752.x. PMID: 8293185. Review.



Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P.
The 2007 WHO classification of tumours of the central nervous system.
Acta Neuropathol. 2007 Jul 6. 2007;114(2):97-109. doi: 10.1007/s00401-007-0243-4. PMID: 17618441. Review.
Erratum in: Acta Neuropathol. 2007 Sep 28. 2007;114(5):547. doi: 10.1007/s00401-007-0278-6. Correction.



Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K.
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.
Cancer Cell. 2006 Mar 1;9(3):157-73. doi: 10.1016/j.ccr.2006.02.019. PMID: 16530701. Laboratory investigation.



Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran T, Wetmore C, Biegel JA, Poggio T, Mukherjee S, Rifkin R, Califano A, Stolovitzky G, Louis DN, Mesirov JP, Lander ES, Golub TR.
Prediction of central nervous system embryonal tumour outcome based on gene expression.
Nature. 2002 Jan 24;415(6870):436-42. doi: 10.1038/415436a. PMID: 11807556. Laboratory investigation.



Etiology, Pathogenesis, Pathology

Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, Small JE, Herrlinger U, Ourednik V, Black PM, Breakefield XO, Snyder EY.
Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas.
Proc Natl Acad Sci USA. 2000 Nov 7;97(23):12846-51. doi: 10.1073/pnas.97.23.12846. PMID: 11070094. Laboratory investigation.
Erratum in: Proc Natl Acad Sci USA. 2001 Jan 16;98(2):777. doi: 10.1073/pnas.98.2.777-d. Correction.



Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN.
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.
Nature. 2006 Oct 18. 2006;444(7120):756-60. doi: 10.1038/nature05236. PMID: 17051156. Laboratory investigation.



Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN.
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor.
Cancer Res. 2006 Aug 15;66(16):7843-8. doi: 10.1158/0008-5472.CAN-06-1010. PMID: 16912155. Laboratory investigation.



Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U, Beier CP.
CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
Cancer Res. 2007 May 1;67(9):4010-5. doi: 10.1158/0008-5472.CAN-06-4180. PMID: 17483311. Laboratory investigation.



Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart CG, Watkins DN, Chen JK, Cooper MK, Taipale J, Olson JM, Beachy PA.
Medulloblastoma growth inhibition by hedgehog pathway blockade.
Science. 2002 Aug 30;297(5586):1559-61. doi: 10.1126/science.1073733. PMID: 12202832. Laboratory investigation.



Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA, Massagué J.
Genes that mediate breast cancer metastasis to the brain.
Nature. 2009 May 6;459(7249):1005-9. doi: 10.1038/nature08021. PMID: 19421193. Laboratory investigation.



Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, Frank A, Bayazitov IT, Zakharenko SS, Gajjar A, Davidoff A, Gilbertson RJ.
A perivascular niche for brain tumor stem cells.
Cancer Cell. 2007 Jan 1;11(1):69-82. doi: 10.1016/j.ccr.2006.11.020. PMID: 17222791. Laboratory investigation.



Chan JA, Krichevsky AM, Kosik KS.
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.
Cancer Res. 2005 Jul 15;65(14):6029-33. doi: 10.1158/0008-5472.CAN-05-0137. PMID: 16024602. Laboratory investigation.



Ciafrè SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, Negrini M, Maira G, Croce CM, Farace MG.
Extensive modulation of a set of microRNAs in primary glioblastoma.
Biochem Biophys Res Commun. 2005 Jul 18;334(4):1351-8. doi: 10.1016/j.bbrc.2005.07.030. PMID: 16039986. Laboratory investigation.



Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A.
HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity.
Curr Biol. 2006 Dec 28. 2007;17(2):165-72. doi: 10.1016/j.cub.2006.11.033. PMID: 17196391. Laboratory investigation.
Erratum in: Curr Biol. 2007 Jan 22;17(2):192. doi: 10.1016/j.cub.2007.01.024. Correction.



Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM.
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Nature. 2009 Nov 22;462(7274):739-44. doi: 10.1038/nature08617. PMID: 19935646. Laboratory investigation.
Addendum in: Nature. 2010 Jun 17;465(7300):966. doi: 10.1038/nature09132. PMID: 20559394. Addendum.



Fulda S, Wick W, Weller M, Debatin KM.
Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.
Nat Med. 2002 Jul 15;8(8):808-15. doi: 10.1038/nm735. PMID: 12118245. Laboratory investigation.



Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK.
Malignant astrocytic glioma: genetics, biology, and paths to treatment.
Genes Dev. 2007 Nov 1;21(21):2683-710. doi: 10.1101/gad.1596707. PMID: 17974913. Review.



Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F, Vescovi A.
Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma.
Cancer Res. 2004 Oct 1;64(19):7011-21. doi: 10.1158/0008-5472.CAN-04-1364. PMID: 15466194. Laboratory investigation.



Giese A, Bjerkvig R, Berens ME, Westphal M.
Cost of migration: invasion of malignant gliomas and implications for treatment.
J Clin Oncol. 2003 Apr 15;21(8):1624-36. doi: 10.1200/JCO.2003.05.063. PMID: 12697889. Review.



Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, Kornblum HI.
Cancerous stem cells can arise from pediatric brain tumors.
Proc Natl Acad Sci USA. 2003 Nov 26;100(25):15178-83. doi: 10.1073/pnas.2036535100. PMID: 14645703. Laboratory investigation.



Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S.
Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells.
Cell Death Differ. 2004 Jan 9;11(4):448-57. doi: 10.1038/sj.cdd.4401359. PMID: 14713959. Laboratory investigation.



Kondo T, Setoguchi T, Taga T.
Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line.
Proc Natl Acad Sci USA. 2004 Jan 7;101(3):781-6. doi: 10.1073/pnas.0307618100. PMID: 14711994. Laboratory investigation.



Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, Park JK, Fine HA.
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.
Cancer Cell. 2006 May 1;9(5):391-403. doi: 10.1016/j.ccr.2006.03.030. PMID: 16697959. Laboratory investigation.



Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A, Schlessinger J.
Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.
Nature. 1985 Jan 10;313(5998):144-7. doi: 10.1038/313144a0. PMID: 2981413. Laboratory investigation.



Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS.
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.
Mol Cancer. 2006 Dec 2;5:67. doi: 10.1186/1476-4598-5-67. PMID: 17140455. Laboratory investigation.



Lyden D, Young AZ, Zagzag D, Yan W, Gerald W, O'Reilly R, Bader BL, Hynes RO, Zhuang Y, Manova K, Benezra R.
Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts.
Nature. 1999 Oct 14;401(6754):670-7. doi: 10.1038/44334. PMID: 10537105. Laboratory investigation.



Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA.
Malignant glioma: genetics and biology of a grave matter.
Genes Dev. 2001 Jun 1;15(11):1311-33. doi: 10.1101/gad.891601. PMID: 11390353. Review.



McLendon R, et al., Cancer Genome Atlas Research Network.
Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
Nature. 2008 Sep 4. 2008;455(7216):1061-8. doi: 10.1038/nature07385. PMID: 18772890. Laboratory investigation.
Erratum in: Nature. 2013 Feb 6. 2013;494(7438):506. doi. 10.1038/nature11903. Correction.



Mercer WE, Shields MT, Amin M, Sauve GJ, Appella E, Romano JW, Ullrich SJ.
Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53.
Proc Natl Acad Sci USA. 1990 Aug 1;87(16):6166-70. doi: 10.1073/pnas.87.16.6166. PMID: 2143581. Laboratory investigation.



Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, Andreeff M, Lang FF.
Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas.
Cancer Res. 2005 Apr 15;65(8):3307-18. doi: 10.1158/0008-5472.CAN-04-1874. PMID: 15833864. Laboratory investigation.
Erratum in: Cancer Res. 2006 Jun 1;66(11):5975
. doi: 10.1158/0008-5472.CAN-66-11-COR1. Correction.



Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJ.
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.
Proc Natl Acad Sci USA. 1994 Aug 2;91(16):7727-31. doi: 10.1073/pnas.91.16.7727. PMID: 8052651. Laboratory investigation.



Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K; Cancer Genome Atlas Research Network.
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.
Cancer Cell. 2010 Apr 15;17(5):510-22. doi: 10.1016/j.ccr.2010.03.017. PMID: 20399149. Laboratory investigation.



Ohgaki H, Kleihues P.
Genetic pathways to primary and secondary glioblastoma.
Am J Pathol. 2007 May 1;170(5):1445-53. doi: 10.2353/ajpath.2007.070011. PMID: 17456751. Review.



Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW.
An integrated genomic analysis of human glioblastoma multiforme.
Science. 2008 Sep 4;321(5897):1807-12. doi: 10.1126/science.1164382. PMID: 18772396. Laboratory investigation.



Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, Brem H, Olivi A, Dimeco F, Vescovi AL.
Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells.
Nature. 2006 Dec 7;444(7120):761-5. doi: 10.1038/nature05349. PMID: 17151667. Laboratory investigation.



Plate KH, Breier G, Weich HA, Risau W.
Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.
Nature. 1992 Oct 29;359(6398):845-8. doi: 10.1038/359845a0. PMID: 1279432. Laboratory investigation.



Seoane J, Le HV, Shen L, Anderson SA, Massagué J.
Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation.
Cell. 2004 Apr 16;117(2):211-23. doi: 10.1016/s0092-8674(04)00298-3. PMID: 15084259. Laboratory investigation.



Shih C, Padhy LC, Murray M, Weinberg RA.
Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts.
Nature. 1981 Mar 19;290(5803):261-4. doi: 10.1038/290261a0. PMID: 7207618. Laboratory investigation.



Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B.
Clonal expansion of p53 mutant cells is associated with brain tumour progression.
Nature. 1992 Feb 27;355(6363):846-7. doi: 10.1038/355846a0. PMID: 1311419. Laboratory investigation.



Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB.
Identification of human brain tumour initiating cells.
Nature. 2004 Nov 18;432(7015):396-401. doi: 10.1038/nature03128. PMID: 15549107. Laboratory investigation.



Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB.
Identification of a cancer stem cell in human brain tumors.
Cancer Res. 2003 Sep 15;63(18):5821-8. PMID: 14522905. Laboratory investigation.



Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT Jr, Carter BS, Krichevsky AM, Breakefield XO.
Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers.
Nat Cell Biol. 2008 Nov 16;10(12):1470-6. doi: 10.1038/ncb1800. PMID: 19011622. Laboratory investigation.



Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN; Cancer Genome Atlas Research Network.
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Cancer Cell. 2010 Jan 19;17(1):98-110. doi: 10.1016/j.ccr.2009.12.020. PMID: 20129251. Laboratory investigation.



Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK.
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.
Cancer Cell. 2004 Dec 1;6(6):553-63. doi: 10.1016/j.ccr.2004.10.011. PMID: 15607960. Laboratory investigation.



Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, Vogelstein B.
Structural alterations of the epidermal growth factor receptor gene in human gliomas.
Proc Natl Acad Sci USA. 1992 Apr 1;89(7):2965-9. doi: 10.1073/pnas.89.7.2965. PMID: 1557402. Laboratory investigation.



Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B.
Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification.
Proc Natl Acad Sci USA. 1987 Oct 1;84(19):6899-903. doi: 10.1073/pnas.84.19.6899. PMID: 3477813. Laboratory investigation.



Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD.
IDH1 and IDH2 mutations in gliomas.
N Engl J Med. 2009 Feb 19;360(8):765-73. doi: 10.1056/NEJMoa0808710. PMID: 19228619. Laboratory investigation.



Overall management

DeAngelis LM.
Brain tumors.
N Engl J Med. 2001 Jan 11;344(2):114-23. doi: 10.1056/NEJM200101113440207. PMID: 11150363. Review.



Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG.
Response criteria for phase II studies of supratentorial malignant glioma.
J Clin Oncol. 1990 Jul;8(7):1277-80. doi: 10.1200/JCO.1990.8.7.1277. PMID: 2358840. Guidelines.



Áfra D.
Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials.
Lancet. 2002 Mar 23;359(9311):1011-8. doi: 10.1016/s0140-6736(02)08091-1. PMID: 11937180. Review.



Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM.
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
J Clin Oncol. 2010 Mar 15;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. PMID: 20231676. Guidelines.



Wen PY, Kesari S.
Malignant gliomas in adults.
N Engl J Med. 2008 Jul 31;359(5):492-507. doi: 10.1056/NEJMra0708126. PMID: 18669428. Review.
Erratum in: N Engl J Med. 2008 Aug 21;359(8):877. doi: 10.1056/NEJMx080027. Correction.



Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P.
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.
Eur J Cancer. 1999 Dec 1;35(13):1773-82. doi: 10.1016/s0959-8049(99)00229-4. PMID: 10673991. Guidelines.



Treatment

Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran WJ Jr.
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.
Lancet. 2004 May 22;363(9422):1665-72. doi: 10.1016/S0140-6736(04)16250-8. PMID: 15158627. Phase 3 trial.



Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura H, Kunieda E, Inomata T, Hayakawa K, Katoh N, Kobashi G.
Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.
JAMA. 2006 Jun 7;295(21):2483-91. doi: 10.1001/jama.295.21.2483. PMID: 16757720. Prospective study.



Aronen HJ, Gazit IE, Louis DN, Buchbinder BR, Pardo FS, Weisskoff RM, Harsh GR, Cosgrove GR, Halpern EF, Hochberg FH, et al.
Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings.
Radiology. 1994 Apr 1;191(1):41-51. doi: 10.1148/radiology.191.1.8134596. PMID: 8134596. Retrospective analysis.



Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK.
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
Cancer Cell. 2007 Jan 15;11(1):83-95. doi: 10.1016/j.ccr.2006.11.021 . PMID: 17222792. Phase 2 trial.



Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Schold SC.
Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group.
Lancet. 1995 Apr 22;345(8956):1008-12. doi: 10.1016/s0140-6736(95)90755-6. PMID: 7723496. Prospective study.



Burger PC, Vogel FS, Green SB, Strike TA.
Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications.
Cancer. 1985 Sep 1;56(5):1106-11. doi: 10.1002/1097-0142(19850901)56:5<1106::aid-cncr2820560525>3.0.co;2-2. PMID: 2990664. Retrospective analysis.



Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN.
Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9. doi: 10.1093/jnci/90.19.1473. PMID: 9776413. Retrospective analysis.



Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA.
Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.
Lancet Oncol. 2009 Oct 5;10(11):1037-44. doi: 10.1016/S1470-2045(09)70263-3. PMID: 19801201. Prospective study.



Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM.
In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors.
Science. 1992 Jun 12;256(5063):1550-2. doi: 10.1126/science.1317968. PMID: 1317968. Laboratory investigation.



Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, et al.
Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.
J Natl Cancer Inst. 1993 May 5;85(9):704-10. doi: 10.1093/jnci/85.9.704. PMID: 8478956. Recursive partitioning analysis.



Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH, Patronas NJ, Kufta CV, Kessler RM, Johnston GS, Manning RG, Wolf AP.
Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography.
Neurology. 1982 Dec 1;32(12):1323-9. doi: 10.1212/wnl.32.12.1323. PMID: 6983044. Prospective study;



Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG.
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
N Engl J Med. 2000 Nov 9;343(19):1350-4. doi: 10.1056/NEJM200011093431901. PMID: 11070098. Prospective study.
Erratum in: N Engl J Med 2000 Dec 7;343(23):1740. doi: 10.1056/NEJM200012073432320. Correction.



Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP.
Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.
Cancer. 1993 Apr 15;71(8):2585-97. doi: 10.1002/1097-0142(19930415)71:8<2585::aid-cncr2820710825>3.0.co;2-s. PMID: 8453582. Meta-analysis.



Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T.
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
J Clin Oncol. 2009 Aug 31;27(28):4733-40. doi: 10.1200/JCO.2008.19.8721. PMID: 19720927. Phase 2 trial.



Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R.
Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials.
Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51. doi: 10.1016/s0360-3016(96)00619-0. PMID: 9128946. Retrospective analysis.



Gilbert RW, Kim JH, Posner JB.
Epidural spinal cord compression from metastatic tumor: diagnosis and treatment.
Ann Neurol. 1978 Jan;3(1):40-51. doi: 10.1002/ana.410030107. PMID: 655653. Retrospective analysis.



Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R.
MGMT gene silencing and benefit from temozolomide in glioblastoma.
N Engl J Med. 2005 Mar 10;352(10):997-1003. doi: 10.1056/NEJMoa043331. PMID: 15758010. Clinical trial.



Hochberg FH, Pruitt A.
Assumptions in the radiotherapy of glioblastoma.
Neurology. 1980 Sep 1;30(9):907-11. doi: 10.1212/wnl.30.9.907. PMID: 6252514. Retrospective analysis.



Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA.
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
J Clin Oncol. 2008 Dec 29. 2009;27(5):740-5. doi: 10.1200/JCO.2008.16.3055. PMID: 19114704. Phase 2 trial.



Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R.
A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival.
J Neurosurg. 2001 Aug;95(2):190-8. doi: 10.3171/jns.2001.95.2.0190. PMID: 11780887. Retrospective analysis.



Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL.
Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial
Gene Ther. 2000 May 25;7(10):867-74. doi: 10.1038/sj.gt.3301205. PMID: 10845725. Phase 1 trial.



Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS.
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
N Engl J Med. 2005 Nov 10;353(19):2012-24. doi: 10.1056/NEJMoa051918. PMID: 16282176. Clinical study.
Erratum in: N Engl J Med. 2006 Feb 23;354(8):884. doi: 10.1056/NEJMx060009. Correction.



Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A.
Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant.
Nature. 1994 Feb 10;367(6463):576-9. doi: 10.1038/367576a0. PMID: 8107827. Laboratory investigation.



Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL.
Meningioma: analysis of recurrence and progression following neurosurgical resection.
J Neurosurg. 1985 Jan;62(1):18-24. doi: 10.3171/jns.1985.62.1.0018. PMID: 3964853. Retrospective analysis.



Ohgaki H, Kleihues P.
Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.
J Neuropathol Exp Neurol. 2005 Jun 1;64(6):479-89. doi: 10.1093/jnen/64.6.479. PMID: 15977639. Retrospective analysis & Review.



Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schüler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lütolf UM, Kleihues P.
Genetic pathways to glioblastoma: a population-based study.
Cancer Res. 2004 Oct 1;64(19):6892-9. doi: 10.1158/0008-5472.CAN-04-1337. PMID: 15466178. Retrospective analysis.



Patchell RA, Tibbs PA, Regine WF, Payne R, Saris S, Kryscio RJ, Mohiuddin M, Young B.
Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial.
Lancet. 2005 Jul 21;366(9486):643-8. doi: 10.1016/S0140-6736(05)66954-1. PMID: 16112300. Prospective study.



Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, Markesbery WR, Foon KA, Young B.
Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial.
JAMA. 1998 Nov 4;280(17):1485-9. doi: 10.1001/jama.280.17.1485. PMID: 9809728. Prospective study.



Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B.
A randomized trial of surgery in the treatment of single metastases to the brain.
N Engl J Med. 1990 Feb 22;322(8):494-500. doi: 10.1056/NEJM199002223220802. PMID: 2405271. Prospective study.



Pearce MS, Salotti JA, Little MP, McHugh K, Lee C, Kim KP, Howe NL, Ronckers CM, Rajaraman P, Sir Craft AW, Parker L, Berrington de González A.
Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study.
Lancet. 2012 Jun 7;380(9840):499-505. doi: 10.1016/S0140-6736(12)60815-0. PMID: 22681860. Retrospective analysis.



Ron E, Modan B, Boice JD Jr, Alfandary E, Stovall M, Chetrit A, Katz L.
Tumors of the brain and nervous system after radiotherapy in childhood.
N Engl J Med. 1988 Oct 20;319(16):1033-9. doi: 10.1056/NEJM198810203191601. PMID: 3173432. Retrospective analysis.



Simpson D.
The recurrence of intracranial meningiomas after surgical treatment.
J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39. doi: 10.1136/jnnp.20.1.22. PMID: 13406590. Retrospective analysis.
Erratum in: J Neurol Neurosurg Psychiatry. 1957 May;13(2):155
. Correction.
Erratum in: J Neurol Neurosurg Psychiatry. 1957 Aug;20(3):240
. Correction.



Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB.
Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.
J Clin Oncol. 2000 Feb 1;18(3):636-45. doi: 10.1200/JCO.2000.18.3.636. PMID: 10653879. Laboratory investigation.



Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ; ALA-Glioma Study Group.
Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial.
Lancet Oncol. 2006 Apr 13;7(5):392-401. doi: 10.1016/S1470-2045(06)70665-9. PMID: 16648043. Phase 3 trial.



Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group.
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Lancet Oncol. 2009 Mar 9. 2009;10(5):459-66
. doi: 10.1016/S1470-2045(09)70025-7. PMID: 19269895. Phase 3 trial.



Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group.
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
N Engl J Med. 2005 Mar 10;352(10):987-96. doi: 10.1056/NEJMoa043330. PMID: 15758009. Phase 3 trial.



Sugahara T, Korogi Y, Kochi M, Ikushima I, Shigematu Y, Hirai T, Okuda T, Liang L, Ge Y, Komohara Y, Ushio Y, Takahashi M.
Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas.
J Magn Reson Imaging. 1999 Jan;9(1):53-60. doi: 10.1002/(sici)1522-2586(199901)9:1<53::aid-jmri7>3.0.co;2-2. PMID: 10030650. Prospective study.



Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS.
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
J Clin Oncol. 2007 Oct 20;25(30):4722-9. doi: 10.1200/JCO.2007.12.2440. PMID: 17947719. Phase 2 trial.



Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS.
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
Clin Cancer Res. 2007 Feb 15;13(4):1253-9. doi: 10.1158/1078-0432.CCR-06-2309. PMID: 17317837. Phase 2 trial.



Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Owens G, Ransohoff J 2nd, Robertson JT, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA.
Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.
N Engl J Med. 1980 Dec 4;303(23):1323-9. doi: 10.1056/NEJM198012043032303. PMID: 7001230. Prospective study.



Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA.
Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial.
J Neurosurg. 1978 Sep;49(3):333-43. doi: 10.3171/jns.1978.49.3.0333. PMID: 355604. Prospective study.



Wasserstrom WR, Glass JP, Posner JB.
Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients.
Cancer. 1982 Feb 15;49(4):759-72. doi: 10.1002/1097-0142(19820215)49:4<759::aid-cncr2820490427>3.0.co;2-7. PMID: 6895713. Retrospective study.



Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J, Ram Z.
A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
Neuro Oncol. 2003 Apr 1;5(2):79-88. doi: 10.1093/neuonc/5.2.79. PMID: 12672279. Phase 3 trial.



Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK.
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.
J Clin Oncol. 1999 Aug 1;17(8):2572-8. doi: 10.1200/JCO.1999.17.8.2572. PMID: 10561324. Phase 2 trial.



Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA.
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.
Br J Cancer. 2000 Aug 8;83(5):588-93. doi: 10.1054/bjoc.2000.1316. PMID: 10944597. Phase 2 trial.





Bottom